Skip to main content
. 2020 May 1;15:3087–3098. doi: 10.2147/IJN.S241324

Figure 5.

Figure 5

Notes: Antitumor effect of CS-4D5/6e in a 22Rv1 xenograft model. (A) Reduction in prostate tumour volume in each group for 14 days after administration. (n = 6, means ± SD, **P < 0.01). (B) Serum testosterone levels of nude mice in each group for 14 days after administration. (C) Comparison of AKR1C3 expression levels in 22Rv1 xenografted nude mice by Western blot analysis, using rabbit monoclonal anti-AKR1C3 antibody and α-tubulin as a loading control. The dose of INN was 3 mg/kg and that of 6e was 2.5 mg/kg. (D) Western blot and analysed by greyscale scanning AKR1C3 (n = 6, mean ± SD, ns: no significant difference vs vehicle, P > 0.05).

Abbreviations: PBS, phosphate buffered saline; INN, indomethacin; CS, chemically chitosan; 4D5, single chain antibody fragment 4D5; 6e, a derivative of mansonone F; AR, androgen receptor; AKR1C3, aldo-ketoreductase1C3; SD, standard deviation.